The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
Abstract Background Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and management of MS is summarized in the article. The r...
Main Authors: | Aleksina Shatilova, Larisa Girshova, Daniil Zaytsev, Irina Budaeva, Yuliya Mirolyubova, Darya Ryzhkova, Roman Grozov, Konstantin Bogdanov, Tatiana Nikulina, Dmitriy Motorin, Darina Zammoeva, Svetlana Efremova, Vladimir Ivanov, Alexey Petukhov, Yuliya Alekseeva, Andrey Zaritskey |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Women's Health |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12905-021-01328-y |
Similar Items
-
Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
by: Tong J, et al.
Published: (2021-07-01) -
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01) -
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01) -
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021-05-01) -
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
by: Hyunsoo Cho, et al.
Published: (2021-04-01)